PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1485738
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1485738
HERG Screening Market size was valued at USD 1,124.45 million in 2023, expanding at a CAGR of 10.9% from 2024 to 2032.
The HERG screening market, vital in drug development to assess compounds for cardiac safety, is driven by stringent drug safety regulations necessitating early cardiac risk identification, alongside a rising incidence of cardiac disorders globally. Advancements in drug discovery technologies and precision medicine further bolster demand for sophisticated HERG screening methods. However, challenges such as high equipment costs, data complexity, and ethical concerns around animal models restrict market growth. Opportunities lie in untapped emerging markets, continuous technological advancements enhancing screening efficiency, strategic collaborations between pharmaceutical entities, and screening providers driving innovation in HERG screening tailored for specific therapeutic areas.
HERG Screening Market- Market Dynamics
Rising Drug Innovation and Cardiovascular Disease Prevalence Driving the Market Growth
The HERG screening market is experiencing robust growth driven by increasing drug innovation and the rising prevalence of cardiovascular diseases. For instance, according to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, with an estimated 17.9 million deaths annually. Additionally, the U.S. Food and Drug Administration (FDA) emphasizes the importance of cardiac safety assessments during drug development to mitigate adverse effects, highlighting the critical role of HERG screening. With pharmaceutical companies focusing on developing novel drugs and therapies, the demand for HERG screening services continues to escalate, ensuring safer and more effective treatments for cardiovascular conditions.
HERG Screening Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.9% over the forecast period (2024-2032)
Based on Type segmentation, Gene KCNH2 was predicted to show maximum market share in the year 2023
Based on Ion Channel segmentation, voltage-gated ion channel was the leading type in 2023
Based on Testing Methods segmentation, Automated Electrophysiology Systems was the leading type in 2023
Based on Application segmentation, Antiarrhythmic was the leading type in 2023
Based on end-user segmentation, Pharmaceutical Companies were the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global HERG Screening Market is segmented based on Type, ION Channel, Testing Methods, Application, End User, and Region.
The market is divided into two categories based on Type: Gene KCNH2 and mutant KCNH2. gene KCNH2 is highly preferred due to its relevance in assessing normal cardiac function and drug interactions. Mutant KCNH2 is secondary preferred, focusing on specific variants for targeted studies and drug response evaluations.
The market is divided into four categories based on ION Channel: Voltage-Gated Ion Channel, Ligand-Gated Ion Channel, Mechanosensitive, and Transient receptor potential. Voltage-gated ion channels are highly preferred due to their central role in cardiac function and drug-induced arrhythmia. Ligand-gated ion channels follow, important for specific drug interactions. Mechanosensitive and transient receptor potential channels are less commonly prioritized for cardiac safety assessments.
HERG Screening Market- Geographical Insights
North America dominates the market due to the presence of a well-established pharmaceutical industry and stringent regulatory standards emphasizing cardiac safety. The region is also characterized by substantial investments in research and development, particularly in innovative drug discovery. Europe follows closely, driven by similar regulatory frameworks and a significant focus on precision medicine. Asia Pacific showcases rapid growth potential attributed to increasing healthcare expenditure, expanding pharmaceutical sector, and rising awareness about drug safety. Emerging economies in this region, such as China and India, are witnessing growing adoption of HERG screening technologies fueled by advancements in healthcare infrastructure and a burgeoning demand for novel therapeutics. These geographical insights underscore the global reach and evolving landscape of the HERG screening market.
Key companies such as Charles River Laboratories International Inc., Cyprotex PLC, Eurofins Scientific, and Cerep SA are prominent players offering comprehensive HERG screening services. These companies focus on leveraging advanced technologies like automated patch clamping and high-throughput screening to enhance efficiency and accuracy in cardiac safety assessments. Strategic partnerships and collaborations with pharmaceutical giants enable them to broaden their market reach and offer tailored solutions. Additionally, emerging players like Nanion Technologies and Sophion Bioscience are gaining traction with novel HERG screening platforms catering to diverse drug development needs. Furthermore, one notable instance of collaboration in the HERG screening market is the partnership between Charles River Laboratories International Inc. and AstraZeneca. This collaboration aimed to develop and validate a new cardiac safety testing panel, including HERG screening assays, to support drug discovery and development efforts.
In August 2023, Metrion Biosciences Limited was accepted into the UK GLP Compliance Monitoring Programme by the Medicines and Healthcare Products Regulatory Agency (MHRA). This allows the company to provide GLP-compliant hERG ion channel screening services worldwide.
In March 2020, Charles River Laboratories and Deciphex have partnered to co-develop deep learning-enabled pathology analytics. Charles River will exclusively offer Deciphex's Patholytix preclinical solution.
GLOBAL HERG SCREENING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Aurora Biomed Inc.
Axion Biosystems
Cerep SA (a part of Eurofins Scientific)
Charles River Laboratories International, Inc.
Confluence Discovery Technologies
Cyprotex (a division of Evotec SE)
Cytocentrics AG
Eurofins Discovery
Icagen, Inc. (a division of Domain Therapeutics)
Metrion Biosciences Ltd.
MilliporeSigma (Merck KGaA)
Nanion Technologies GmbH
Ncardia
PerkinElmer, Inc.
SB Drug Discovery
Sophion Bioscience A/S
Others